Detalhe da pesquisa
1.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
2.
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol
; 175: 1-7, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262961
3.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298906
4.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
5.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
6.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
7.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
8.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103386
9.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593565
10.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359490
11.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861537
12.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer
; 29(9): 1396-1404, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685558
13.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
14.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
15.
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Br J Cancer
; 116(7): 884-892, 2017 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222073
16.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
17.
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
J Clin Oncol
; 42(11): 1301-1310, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215359
18.
Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis.
Eur J Pediatr
; 172(9): 1235-42, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23677249
19.
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
EBioMedicine
; 89: 104477, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801617
20.
Race and insurance status are risk factors for orchiectomy due to testicular trauma.
J Urol
; 187(3): 931-5, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22264470